{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:11Z","timestamp":1791995651135,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, disabling genetic disorder condition that lacks real-world evidence on disease burden. This study aims to investigate the basic characteristics, diagnostic status, prognosis, economic burden and quality of life of FOP patients in China through self-reported data .<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>An online survey was conducted through the \u201cChina Cloud Platform for Rare Diseases\u201d among patients recruited from the FOP patient organization in March 2023. Patient demographic characteristics, diagnosis, prognosis, healthcare resource usage and costs, and health-related quality of life (HRQoL) data were collected. Health-related quality of life was assessed using EQ-5D-Y for children aged 4\u201315 and EQ-5D-5L for patients aged\u2009\u2265\u200916. Age subgroup analyses for those aged\u2009&lt;\u20098, 8\u201315, and\u2009\u2265\u200916 were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 67 patients (mean age 16.6\u2009\u00b1\u200910.2 years, 43.3% female) were included. The average delay of confirmed diagnosis was 3.1\u2009\u00b1\u20094.3 years. 98.5% of patients were disabled due to FOP. Only 38.8% of the patients had outpatient or inpatient visits in the past year. The annual cost per patient was USD 10,820\u2009\u00b1\u200910,894, with 75.2% being indirect costs. Health utility values were lowest for patients aged\u2009\u2265\u200916 (0.221\u2009\u00b1\u20090.336), compared to those aged\u2009&lt;\u20098 (0.700\u2009\u00b1\u20090.163) and those aged 8\u201315 (0.618\u2009\u00b1\u20090.202).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>FOP patients suffer long delay diagnosis duration, high disability rates in China. A significant disease burden was driven by high indirect costs and poor quality of life. Patients aged\u2009\u2265\u200916 have the worst health-related quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03884-0","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:53:50Z","timestamp":1754582030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaoyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-2785","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"3884_CR1","first-page":"1","volume":"4","author":"FS Kaplan","year":"2022","unstructured":"Kaplan FS. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2022;4:1.","journal-title":"Proc Intl Clin Council FOP."},{"issue":"1","key":"3884_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191\u2013205.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"3884_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s12325-022-02096-3","volume":"39","author":"JT Markowitz","year":"2022","unstructured":"Markowitz JT, Rofail D, Vandenberg G, et al. \u201cI can\u2019t take off my shirt or do my own hair\u201d-a qualitative investigation of the symptoms and impact experience of children and adolescents with fibrodysplasia ossificans progressiva (FOP). Adv Ther. 2022;39(6):2796\u2013805.","journal-title":"Adv Ther"},{"issue":"3","key":"3884_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686\u201391.","journal-title":"J Bone Joint Surg Am."},{"key":"3884_CR5","unstructured":"Yin L, Zhou Y, et al. Fibrodysplasia ossificans progressiva: 4 cases report and literature review. J Clin Pediatr 2011:29(07):685-689."},{"issue":"5","key":"3884_CR6","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1542\/peds.2005-0469","volume":"116","author":"JA Kitterman","year":"2005","unstructured":"Kitterman JA, Kantanie S, Rocke DM, et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654-61.","journal-title":"Pediatrics"},{"key":"3884_CR7","first-page":"437","volume":"10","author":"RJ Pignolo","year":"2013","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10:437\u201348.","journal-title":"Pediatr Endocrinol Rev."},{"issue":"1","key":"3884_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13023-019-1068-7","volume":"14","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):98.","journal-title":"Orphanet J Rare Dis."},{"issue":"12","key":"3884_CR9","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","volume":"24","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422\u201333.","journal-title":"Genet Med."},{"issue":"3","key":"3884_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (fop): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136.","journal-title":"J Bone Miner Res."},{"issue":"8","key":"3884_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/14737167.2022.2115360","volume":"22","author":"M Al Mukaddam","year":"2022","unstructured":"Al Mukaddam M, Toder KS, Davis M, et al. The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1199\u2013213.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"3884_CR12","doi-asserted-by":"publisher","first-page":"115274","DOI":"10.1016\/j.bone.2020.115274","volume":"134","author":"RJ Pignolo","year":"2020","unstructured":"Pignolo RJ, Cheung K, Kile S, et al. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone. 2020;134:115274.","journal-title":"Bone"},{"issue":"6","key":"3884_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11832-015-0704-6","volume":"9","author":"F Ortiz-Agapito","year":"2015","unstructured":"Ortiz-Agapito F, Colmenares-Bonilla D. Quality of life of patients with fibrodysplasia ossificans progressiva. J Child Orthop. 2015;9(6):489\u201393.","journal-title":"J Child Orthop."},{"issue":"6","key":"3884_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/09638288.2017.1405083","volume":"41","author":"Y Nakahara","year":"2019","unstructured":"Nakahara Y, Kitoh H, Nakashima Y, et al. Longitudinal study of the activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva. Disabil Rehabil. 2019;41(6):699\u2013704.","journal-title":"Disabil Rehabil."},{"key":"3884_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bone.2017.08.032","volume":"109","author":"N Mantick","year":"2018","unstructured":"Mantick N, Bachman E, Baujat G, et al. The FOP connection registry: design of an international patient-sponsored registry for fibrodysplasia ossificans progressiva. Bone. 2018;109:285\u201390.","journal-title":"Bone"},{"key":"3884_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2017.11.016","volume":"109","author":"D She","year":"2018","unstructured":"She D, Zhang K. Fibrodysplasia ossificans progressiva in China. Bone. 2018;109:101\u20133.","journal-title":"Bone"},{"issue":"Suppl 2","key":"3884_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40273-022-01216-9","volume":"40","author":"Z Yang","year":"2022","unstructured":"Yang Z, Jiang J, Wang P, et al. Estimating an EQ-5D-Y-3L value set for China. Pharmacoeconomics. 2022;40(Suppl 2):147\u201355.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, et al. Estimating an EQ-5D-5L Value Set for China. Value Health. 2017;20(4):662\u20139.","journal-title":"Value Health"},{"issue":"8","key":"3884_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10181","volume":"3","author":"K Peng","year":"2019","unstructured":"Peng K, Cheung K, Lee A, et al. Longitudinal evaluation of pain, flare-up, and emotional health in fibrodysplasia ossificans progressiva: analyses of the international FOP registry. JBMR Plus. 2019;3(8): e10181.","journal-title":"JBMR Plus"},{"issue":"2","key":"3884_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2013.09.002","volume":"57","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zhang K, Song L, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386\u201391.","journal-title":"Bone"},{"issue":"9","key":"3884_CR21","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jval.2022.04.1725","volume":"25","author":"YNC Ng","year":"2022","unstructured":"Ng YNC, Ng NYT, Fung JLF, et al. Evaluating the health-related quality of life of the rare disease population in hong kong using eq-5d 3-level. Value Health. 2022;25(9):1624\u201333.","journal-title":"Value Health"},{"key":"3884_CR22","doi-asserted-by":"publisher","DOI":"10.2196\/50147","volume":"9","author":"RH Xu","year":"2023","unstructured":"Xu RH, Ng SSM, Luo N, et al. Measurement of health-related quality of life in individuals with rare diseases in china: nation-wide online survey. JMIR Public Health Surveill. 2023;9: e50147.","journal-title":"JMIR Public Health Surveill."},{"key":"3884_CR23","doi-asserted-by":"publisher","first-page":"732728","DOI":"10.3389\/fendo.2021.732728","volume":"12","author":"RD De Ruiter","year":"2021","unstructured":"De Ruiter RD, Smilde BJ, Pals G, et al. Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Front Endocrinol. 2021;12:732728.","journal-title":"Front Endocrinol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03884-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03884-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03884-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:33:58Z","timestamp":1757352838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03884-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03884-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Academic Ethics Committee at Tianjin University on December 15, 2022 (TJUE-2022-291) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Participants were informed about their freedom of refusal. Anonymity and confidentiality were maintained throughout the research process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our research manuscript has obtained the necessary consent from the individuals concerned.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}